Abstract: The invention provides conjugates, comprising an organ or tissue targeting moiety linked to a biologically active moiety or linked to a diagnostic moiety. Such a biologically active or diagnostic moiety can be, for example, an oligonucleotide, small interfering RNA, a gene, a virus, a protein, a drug, a small organic molecule, a pharmaceutical, or a detectable agent.

Abstract: The present invention relates to ether-linked triazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators.

Abstract: The invention provides conjugates, comprising an organ or tissue targeting moiety linked to a biologically active moiety or linked to a diagnostic moiety. Such a biologically active or diagnostic moiety can be, for example, an oligonucleotide, small interfering RNA, a gene, a virus, a protein, a drug, a small organic molecule, a pharmaceutical, or a detectable agent.

Abstract: The present invention relates to ether-linked triazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators.

Abstract: The present invention relates to ether-linked triazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators.

Abstract: The present invention relates to N-aryl pyrazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.

Abstract: A process for converting a biomass-derived pyrolysis oil in which the pyrolysis oil is contacted with hydrogen in the presence of a certain catalyst containing one or more Group VIII metals is provided. The catalyst is prepared by (a) comulling (1) a refractory oxide, (2) a small amount of liquid, chosen such that the Loss On Ignition (LOI) at 485° C. of the mixture is from equal to or more than 20 wt % to equal to or less than 70 wt % based on the total weight of the catalyst composition, and (3) at least one or more metal component(s), which is/are at least partially insoluble in the amount of liquid used, to form a mixture, and the metal component(s) is/are one or more Group VIII metal component, (b) optionally shaping, and drying of the mixture thus obtained; and (c) calcining the composition thus obtained to provide a calcined catalyst.

Abstract: The present invention relates to biaryl pyrazole compounds of Formula (I) methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.

Abstract: The present invention relates to bis aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.

Abstract: The present invention relates to bis aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.

Abstract: The present invention relates to biaryl pyrazole compounds of Formula (I) methods of making them, pharmaceutical compositions containing them and their use as NRF2 regulators.

Abstract: The present invention relates to aryl analogs Formula (I), pharmaceutical compositions containing them and their use as Nrf2 regulators.

Abstract: Described are amphiphilic polymers that are provided with chelating moieties. The amphiphilic polymers are block copolymers comprising a hydrophilic block and a hydrophobic block, with the chelating moieties linked to the end-group of the hydrophilic block. The disclosed polymers are capable of self-assembly into structures such as micelles and polymersomes. With suitable metals present in the form of coordination complexes with the chelating moieties, the chelating amphiphilic polymers of the invention are suitable for use in various imaging techniques requiring metal labeling, such as MRI (T1/T2 weighted contrast agents or CEST contrast agents) SPECT, PET or Spectral CT.

Abstract: Disclosed are carriers for drugs and/or MR imaging agents having a lipid bilayer shell comprising a phospholipid having two terminal alkyl chains, one being a short chain having a chain length of at most seven carbon atoms, the other being a long chain having a chain length of at least fifteen carbon atoms. The mixed long/short chain phospholipids serve to tune the release properties of the carrier. Preferred phospholipids are phosphatidylcholines.

Abstract: A process for converting a biomass-derived pyrolysis oil in which the pyrolysis oil is contacted with hydrogen in the presence of a certain catalyst containing one or more Group VIII metals is provided. The catalyst is prepared by (a) comulling (1) a refractory oxide, (2) a small amount of liquid, chosen such that the Loss On Ignition (LOI) at 485° C. of the mixture is from equal to or more than 20 wt % to equal to or less than 70 wt % based on the total weight of the catalyst composition, and (3) at least one or more metal component(s), which is/are at least partially insoluble in the amount of liquid used, to form a mixture, and the metal component(s) is/are one or more Group VIII metal component, (b) optionally shaping, and drying of the mixture thus obtained; and (c) calcination of the composition thus obtained to provide a calcined catalyst.

Abstract: The present invention relates to bis aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.

Abstract: The invention relates to a flexible electrical generator comprising at least one photovoltaic device and a flexible support, wherein said photovoltaic device is attached to the flexible support and wherein the flexible support comprises a fabric comprising high-strength polymeric fibers, said flexible support comprising also a plastomer wherein said plastomer is a semi-crystalline copolymer of ethylene or propylene and one or more C2 to C12 ?-olefin co-monomers and wherein said plastomer having a density as measured according to ISO1183 of between 860 and 930 kg/m3.

Abstract: The invention provides compounds that are useful in the treatment of hepatitis C virus (HCV) infections.

Abstract: Described are amphiphilic polymers that are provided with chelating moieties. The amphiphilic polymers are block copolymers comprising a hydrophilic block and a hydrophobic block, with the chelating moieties linked to the end-group of the hydrophilic block. The disclosed polymers are capable of self-assembly into structures such as micelles and polymersomes. With suitable metals present in the form of coordination complexes with the chelating moieties, the chelating amphiphilic polymers of the invention are suitable for use in various imaging techniques requiring metal labeling, such as MRI (T1/T2 weighted contrast agents or CEST contrast agents) SPECT, PET or Spectral CT.

Abstract: The invention provides compounds that are useful in the treatment of hepatitis C virus (HCV) infections.